Loading…

Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)

The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients for low-dose aspirin deprescribing is unknown. To apply the 3 low-dose aspiri...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2020-12, Vol.137, p.25-30
Main Authors: Ong, Shawn Y., Chui, Philip, Bhargava, Ankur, Justice, Amy, Hauser, Ronald G.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3
cites cdi_FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3
container_end_page 30
container_issue
container_start_page 25
container_title The American journal of cardiology
container_volume 137
creator Ong, Shawn Y.
Chui, Philip
Bhargava, Ankur
Justice, Amy
Hauser, Ronald G.
description The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients for low-dose aspirin deprescribing is unknown. To apply the 3 low-dose aspirin guidelines to EHR data, the guidelines were deconstructed into components from their narrative text and assigned computer-interpretable definitions based on electronic data interchange standards. These definitions were used to search EHR data to identify patients for aspirin deprescribing. To verify EHR records for low-dose aspirin, we then compared the records with a survey of patients’ self-reported use of low-dose aspirin. Of the 3 aspirin guidelines, only 1 had a definition suitable for EHR implementation. The other 2 contained difficult-to-implement phrases (e.g., “higher ASCVD risk”, “increased bleeding risk”). An EHR search with the single implementable guideline identified 86,555 people for possible aspirin deprescribing (2% of 5,598,604). Only 676 of 1,135 (60%) patients who self-reported taking low-dose aspirin had an active EHR record for low-dose aspirin at that time. Limitations exist when using EHR data to identify patients for possible low-dose aspirin deprescribing such as incomplete EHR capture of and the interpretation of non-specific terminology when translating guidelines into an electronic equivalent. In conclusion, data show many people unnecessarily take low-dose aspirin. •Electronic health records do not capture many people on low-dose aspirin.•Guidelines for low-dose aspirin are difficult to apply to electronic data at a population level.•Electronic data show that many people qualify for aspirin overuse.•Opportunities exist for aspirin deprescription.
doi_str_mv 10.1016/j.amjcard.2020.09.042
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2463607617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914920310171</els_id><sourcerecordid>2463607617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3</originalsourceid><addsrcrecordid>eNqFUE1LAzEUDKJo_fgJSsCLHnZNsl_NSUqtHyAqqOeQzb5olu6mJtmKR_-5Ka1eveQR3sy8mUHomJKUElpetKnsWiVdkzLCSEp4SnK2hUZ0XPGEcpptoxEhhCWc5nwP7Xvfxi-lRbmL9jLGOR0XbIS-Zz6YTgbTv-GJXxhnevy4BDd4wNo6_OTi1n3FCUvog7E9thpPwjs469U8vsEoPI0-jF1Kr4a5dPjKeJBR4Ew722GJH-SK-GkawLcg5-E9-gb8_OUDdOeHaEfLuYejzTxAr9ezl-ltcv94czed3Ccq41lImNIyowXXVHNdaQkFzzmrZAkxd1VpLWtWQ1nnq9CQa0kKNs4VwLjKGpnX2QE6XesunP0YwAfR2sH18aRgeZmVpCppFVHFGqViPu9Ai8W6AUGJWBUvWrEpXqyKF4SLaCDyTjbqQ91B88f6bToCLtcAiBmXBpzwykCvoDEOVBCNNf-c-AGmu5k4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2463607617</pqid></control><display><type>article</type><title>Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)</title><source>Elsevier</source><creator>Ong, Shawn Y. ; Chui, Philip ; Bhargava, Ankur ; Justice, Amy ; Hauser, Ronald G.</creator><creatorcontrib>Ong, Shawn Y. ; Chui, Philip ; Bhargava, Ankur ; Justice, Amy ; Hauser, Ronald G.</creatorcontrib><description>The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients for low-dose aspirin deprescribing is unknown. To apply the 3 low-dose aspirin guidelines to EHR data, the guidelines were deconstructed into components from their narrative text and assigned computer-interpretable definitions based on electronic data interchange standards. These definitions were used to search EHR data to identify patients for aspirin deprescribing. To verify EHR records for low-dose aspirin, we then compared the records with a survey of patients’ self-reported use of low-dose aspirin. Of the 3 aspirin guidelines, only 1 had a definition suitable for EHR implementation. The other 2 contained difficult-to-implement phrases (e.g., “higher ASCVD risk”, “increased bleeding risk”). An EHR search with the single implementable guideline identified 86,555 people for possible aspirin deprescribing (2% of 5,598,604). Only 676 of 1,135 (60%) patients who self-reported taking low-dose aspirin had an active EHR record for low-dose aspirin at that time. Limitations exist when using EHR data to identify patients for possible low-dose aspirin deprescribing such as incomplete EHR capture of and the interpretation of non-specific terminology when translating guidelines into an electronic equivalent. In conclusion, data show many people unnecessarily take low-dose aspirin. •Electronic health records do not capture many people on low-dose aspirin.•Guidelines for low-dose aspirin are difficult to apply to electronic data at a population level.•Electronic data show that many people qualify for aspirin overuse.•Opportunities exist for aspirin deprescription.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2020.09.042</identifier><identifier>PMID: 32991852</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Age ; Aged ; Aged, 80 and over ; Angina pectoris ; Anticoagulants ; Arteriosclerosis ; Aspirin ; Aspirin - therapeutic use ; Atherosclerosis ; Atherosclerosis - drug therapy ; Bleeding ; Cardiology ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - prevention &amp; control ; Data search ; Delivery of Health Care - statistics &amp; numerical data ; Disease prevention ; Drug Overdose - epidemiology ; Electronic data interchange ; Electronic Health Records ; Electronic medical records ; Female ; Guidelines ; Health care policy ; Heart attacks ; Humans ; Male ; Middle Aged ; Patients ; Platelet Aggregation Inhibitors - therapeutic use ; Population ; Primary care ; Primary Prevention - methods ; Risk Factors ; Terminology ; United States - epidemiology ; Veterans ; Young Adult</subject><ispartof>The American journal of cardiology, 2020-12, Vol.137, p.25-30</ispartof><rights>2020</rights><rights>Published by Elsevier Inc.</rights><rights>Copyright Elsevier Limited Dec 15, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3</citedby><cites>FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3</cites><orcidid>0000-0002-7361-7162 ; 0000-0003-0957-7116 ; 0000-0002-9382-1355 ; 0000-0003-0139-5502</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32991852$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ong, Shawn Y.</creatorcontrib><creatorcontrib>Chui, Philip</creatorcontrib><creatorcontrib>Bhargava, Ankur</creatorcontrib><creatorcontrib>Justice, Amy</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><title>Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients for low-dose aspirin deprescribing is unknown. To apply the 3 low-dose aspirin guidelines to EHR data, the guidelines were deconstructed into components from their narrative text and assigned computer-interpretable definitions based on electronic data interchange standards. These definitions were used to search EHR data to identify patients for aspirin deprescribing. To verify EHR records for low-dose aspirin, we then compared the records with a survey of patients’ self-reported use of low-dose aspirin. Of the 3 aspirin guidelines, only 1 had a definition suitable for EHR implementation. The other 2 contained difficult-to-implement phrases (e.g., “higher ASCVD risk”, “increased bleeding risk”). An EHR search with the single implementable guideline identified 86,555 people for possible aspirin deprescribing (2% of 5,598,604). Only 676 of 1,135 (60%) patients who self-reported taking low-dose aspirin had an active EHR record for low-dose aspirin at that time. Limitations exist when using EHR data to identify patients for possible low-dose aspirin deprescribing such as incomplete EHR capture of and the interpretation of non-specific terminology when translating guidelines into an electronic equivalent. In conclusion, data show many people unnecessarily take low-dose aspirin. •Electronic health records do not capture many people on low-dose aspirin.•Guidelines for low-dose aspirin are difficult to apply to electronic data at a population level.•Electronic data show that many people qualify for aspirin overuse.•Opportunities exist for aspirin deprescription.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angina pectoris</subject><subject>Anticoagulants</subject><subject>Arteriosclerosis</subject><subject>Aspirin</subject><subject>Aspirin - therapeutic use</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - drug therapy</subject><subject>Bleeding</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - prevention &amp; control</subject><subject>Data search</subject><subject>Delivery of Health Care - statistics &amp; numerical data</subject><subject>Disease prevention</subject><subject>Drug Overdose - epidemiology</subject><subject>Electronic data interchange</subject><subject>Electronic Health Records</subject><subject>Electronic medical records</subject><subject>Female</subject><subject>Guidelines</subject><subject>Health care policy</subject><subject>Heart attacks</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Population</subject><subject>Primary care</subject><subject>Primary Prevention - methods</subject><subject>Risk Factors</subject><subject>Terminology</subject><subject>United States - epidemiology</subject><subject>Veterans</subject><subject>Young Adult</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFUE1LAzEUDKJo_fgJSsCLHnZNsl_NSUqtHyAqqOeQzb5olu6mJtmKR_-5Ka1eveQR3sy8mUHomJKUElpetKnsWiVdkzLCSEp4SnK2hUZ0XPGEcpptoxEhhCWc5nwP7Xvfxi-lRbmL9jLGOR0XbIS-Zz6YTgbTv-GJXxhnevy4BDd4wNo6_OTi1n3FCUvog7E9thpPwjs469U8vsEoPI0-jF1Kr4a5dPjKeJBR4Ew722GJH-SK-GkawLcg5-E9-gb8_OUDdOeHaEfLuYejzTxAr9ezl-ltcv94czed3Ccq41lImNIyowXXVHNdaQkFzzmrZAkxd1VpLWtWQ1nnq9CQa0kKNs4VwLjKGpnX2QE6XesunP0YwAfR2sH18aRgeZmVpCppFVHFGqViPu9Ai8W6AUGJWBUvWrEpXqyKF4SLaCDyTjbqQ91B88f6bToCLtcAiBmXBpzwykCvoDEOVBCNNf-c-AGmu5k4</recordid><startdate>20201215</startdate><enddate>20201215</enddate><creator>Ong, Shawn Y.</creator><creator>Chui, Philip</creator><creator>Bhargava, Ankur</creator><creator>Justice, Amy</creator><creator>Hauser, Ronald G.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0003-0957-7116</orcidid><orcidid>https://orcid.org/0000-0002-9382-1355</orcidid><orcidid>https://orcid.org/0000-0003-0139-5502</orcidid></search><sort><creationdate>20201215</creationdate><title>Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)</title><author>Ong, Shawn Y. ; Chui, Philip ; Bhargava, Ankur ; Justice, Amy ; Hauser, Ronald G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angina pectoris</topic><topic>Anticoagulants</topic><topic>Arteriosclerosis</topic><topic>Aspirin</topic><topic>Aspirin - therapeutic use</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - drug therapy</topic><topic>Bleeding</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - prevention &amp; control</topic><topic>Data search</topic><topic>Delivery of Health Care - statistics &amp; numerical data</topic><topic>Disease prevention</topic><topic>Drug Overdose - epidemiology</topic><topic>Electronic data interchange</topic><topic>Electronic Health Records</topic><topic>Electronic medical records</topic><topic>Female</topic><topic>Guidelines</topic><topic>Health care policy</topic><topic>Heart attacks</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Population</topic><topic>Primary care</topic><topic>Primary Prevention - methods</topic><topic>Risk Factors</topic><topic>Terminology</topic><topic>United States - epidemiology</topic><topic>Veterans</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ong, Shawn Y.</creatorcontrib><creatorcontrib>Chui, Philip</creatorcontrib><creatorcontrib>Bhargava, Ankur</creatorcontrib><creatorcontrib>Justice, Amy</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ong, Shawn Y.</au><au>Chui, Philip</au><au>Bhargava, Ankur</au><au>Justice, Amy</au><au>Hauser, Ronald G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2020-12-15</date><risdate>2020</risdate><volume>137</volume><spage>25</spage><epage>30</epage><pages>25-30</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><abstract>The American College of Cardiology and American Heart Association recently published guidelines narrowing the indications for low-dose aspirin use. The suitability of the electronic health record (EHR) to identify patients for low-dose aspirin deprescribing is unknown. To apply the 3 low-dose aspirin guidelines to EHR data, the guidelines were deconstructed into components from their narrative text and assigned computer-interpretable definitions based on electronic data interchange standards. These definitions were used to search EHR data to identify patients for aspirin deprescribing. To verify EHR records for low-dose aspirin, we then compared the records with a survey of patients’ self-reported use of low-dose aspirin. Of the 3 aspirin guidelines, only 1 had a definition suitable for EHR implementation. The other 2 contained difficult-to-implement phrases (e.g., “higher ASCVD risk”, “increased bleeding risk”). An EHR search with the single implementable guideline identified 86,555 people for possible aspirin deprescribing (2% of 5,598,604). Only 676 of 1,135 (60%) patients who self-reported taking low-dose aspirin had an active EHR record for low-dose aspirin at that time. Limitations exist when using EHR data to identify patients for possible low-dose aspirin deprescribing such as incomplete EHR capture of and the interpretation of non-specific terminology when translating guidelines into an electronic equivalent. In conclusion, data show many people unnecessarily take low-dose aspirin. •Electronic health records do not capture many people on low-dose aspirin.•Guidelines for low-dose aspirin are difficult to apply to electronic data at a population level.•Electronic data show that many people qualify for aspirin overuse.•Opportunities exist for aspirin deprescription.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32991852</pmid><doi>10.1016/j.amjcard.2020.09.042</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0003-0957-7116</orcidid><orcidid>https://orcid.org/0000-0002-9382-1355</orcidid><orcidid>https://orcid.org/0000-0003-0139-5502</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0002-9149
ispartof The American journal of cardiology, 2020-12, Vol.137, p.25-30
issn 0002-9149
1879-1913
language eng
recordid cdi_proquest_journals_2463607617
source Elsevier
subjects Adolescent
Adult
Age
Aged
Aged, 80 and over
Angina pectoris
Anticoagulants
Arteriosclerosis
Aspirin
Aspirin - therapeutic use
Atherosclerosis
Atherosclerosis - drug therapy
Bleeding
Cardiology
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - prevention & control
Data search
Delivery of Health Care - statistics & numerical data
Disease prevention
Drug Overdose - epidemiology
Electronic data interchange
Electronic Health Records
Electronic medical records
Female
Guidelines
Health care policy
Heart attacks
Humans
Male
Middle Aged
Patients
Platelet Aggregation Inhibitors - therapeutic use
Population
Primary care
Primary Prevention - methods
Risk Factors
Terminology
United States - epidemiology
Veterans
Young Adult
title Estimating Aspirin Overuse for Primary Prevention of Atherosclerotic Cardiovascular Disease (from a Nationwide Healthcare System)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T22%3A54%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Estimating%20Aspirin%20Overuse%20for%20Primary%20Prevention%20of%20Atherosclerotic%20Cardiovascular%20Disease%20(from%20a%20Nationwide%20Healthcare%20System)&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Ong,%20Shawn%20Y.&rft.date=2020-12-15&rft.volume=137&rft.spage=25&rft.epage=30&rft.pages=25-30&rft.issn=0002-9149&rft.eissn=1879-1913&rft_id=info:doi/10.1016/j.amjcard.2020.09.042&rft_dat=%3Cproquest_cross%3E2463607617%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-2cfa3159f1f9f7fae594927a6e04277ffab2be6b40002e4fa05284cee873da4b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2463607617&rft_id=info:pmid/32991852&rfr_iscdi=true